<DOC>
	<DOC>NCT00434317</DOC>
	<brief_summary>This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.</brief_summary>
	<brief_title>Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criteria: Ambulatory patients &gt;18 years Proof of breast cancer or prostate cancer Diagnosis of at least one cancerrelated bone lesion that is detectable on conventional radiographs or bone scan at screening Negative pregnancy test ECOG performance status of 0,1 or 2 Exclusion criteria: Patients with abnormal renal function Patients with clinically symptomatic brain metastases Known hypersensitivity on zoledronic acid or other bisphosphonates Pregnancy or lactation Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastasis</keyword>
	<keyword>Neoplasm</keyword>
	<keyword>pain</keyword>
	<keyword>breast cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>